

USSN 09/677,822
Page 3

REMARKS

The present application was originally filed with 28 Claims. In a Preliminary Amendment mailed July 17, 2001, Claims 2, 3, and 14-28 were cancelled without prejudice and Claims 29 and 30 were added. Thus, Claims 1, 4-13, 29 and 30 were pending. In response to the present Restriction Requirement, the Examiner has restricted the Claims into two Groups, with Claims 1, 4-10 and 29-30 in Group I, and Claims 11-13 in Group II. Applicants hereby elect the Claims in Group I with traverse, and have cancelled Claims 11-13. Applicants reserve the right to pursue any or all of the cancelled Claims in a Divisional application. Should the Examiner have any questions regarding this application, he is encouraged to call the undersigned.

Respectfully submitted,

Date: October 9, 2002


Kamrin T. MacKnight
Registration No. 38,230

Genencor International, Inc.
925 Page Mill Road
Palo Alto, CA 94304
Tel: 650-846-5838
Fax: 650-845-6504

USSN 09/677,822
Page 4

APPENDIX I

MARKED-UP VERSION REWRITTEN, ADDED, AND/OR CANCELLED CLAIMS

The following is a marked-up version of the Claims pursuant to 37 C.F.R. §1.121 (c)(1)(ii) with instructions and markings showing changes made herein to the previous version of record of the Claims. Underlining denotes added text while bracketing denotes deleted text.

IN THE CLAIMS:

Please cancel Claims 11-13.

USSN 09/677,822

Page 5

APPENDIX II**CLEAN VERSION OF THE ENTIRE SET OF PENDING CLAIMS AS
AMENDED IN THIS COMMUNICATION**

The following is a list of the Claims as they would appear following entry of this amendment.

1. (Once Amended) A variant of a polypeptide of interest comprising a T-cell epitope, wherein said variant differs from said polypeptide of interest by having an altered T-cell epitope such that said variant produces an immunogenic response in an individual which is greater than the immunogenic response produced by said polypeptide of interest.

4. The variant of claim 1 wherein said polypeptide of interest is selected from the group consisting of enzymes, hormones, factors, vaccines and cytokines.

5. The variant of claim 1 wherein said polypeptide of interest is not recognized by said individual as endogenous to said individual.

6. The variant of claim 1 wherein said polypeptide of interest is an enzyme selected from the group consisting of lipase, cellulase, endo-glucosidase H, protease, carbohydrases, reductase, oxidase, isomerase, transferase, kinase and phosphatase.

7. The variant of claim 1 wherein said T-cell epitope is altered with amino acid substitutions.

8. (Once Amended) The variant of claim 1 wherein said T-cell epitope is altered by having a terminal portion of said polypeptide of interest comprising said T-cell epitope replaced with a corresponding terminal portion of a homolog of said polypeptide of interest wherein said homolog does not comprise a T-cell epitope identical to said replaced T-cell epitope.

9. The variant of claim 8 wherein said variant comprises at least one less T-cell epitope than said polypeptide of interest and said homolog combined.

USSN 09/677,822
Page 6

10. The variant of claim 8 wherein said variant comprises at least two less T-cell epitopes than said polypeptide of interest and said homolog combined.

29. The variant of claim 1, wherein said polypeptide of interest is a therapeutic protein.

30. A variant of a polypeptide of interest comprising a T-cell epitope, wherein said variant differs from said polypeptide of interest by having a T-cell epitope that has been altered by amino acid substitutions such that said variant produces an immunogenic response in an individual which is greater than the immunogenic response produced by said polypeptide of interest.